Ground spraying trials with different dosages of deltamethrin wettable poweder (NRDC 161) were carried out against G. palpalis (s.l.), vector of sleeping sickness, in January and November 1981 in the Bouaflé human trypanosomiasis focus, Ivory Coast. Three dosages have been tested: 60 g of active ingredient (a.i.) per ha at a concentration of 0.08% in January; and 20 and 12 g of active ingredient per ha in November at 0.027 and 0.016%, respectively. Each dosage has been applied once as a residual spray; spraying apparatus used was the atomiser Solo Port 423. The knock-down and short-term effects of the insecticide were very satisfactory: 90–98% reduction in apparent density of the vector was obtained during the first 2 months after treatment with all the three dosages applied. In the long term, 2–4 months after spraying, more than 95% reduction in apparent density of G. palpalis (s.l.) was achieved even with the lowest dosage of 12 g (a.i.)/ha. The highest dosage of 60 g (a.i.)/ha does not seem to increase significantly the persistence of the insecticide nor the mortality rate of the vector in the study area. In order to reduce the cost of a tsetse control programme and also to minimise insecticide impact on non-target organisms, it is therefore recommended that deltamethrin w.p. be applied at the lower dosage of 12 g (a.i.)/ha in residual ground spraying.